Stockscreener 앱 받기
991.94
0.41%
4.10
전일 마감가:
$987.84
열려 있는:
$988.49
하루 거래량:
38,250
Relative Volume:
0.12
시가총액:
$61.97B
수익:
$4.16B
순이익/손실:
$1.29B
주가수익비율:
50.65
EPS:
19.5837
순현금흐름:
$734.26M
1주 성능:
+14.70%
1개월 성능:
+15.26%
6개월 성능:
+17.33%
1년 성능:
+49.98%
1일 변동 폭
$980.45
$993.39
1주일 범위
$837.42
$1,002.16
52주 변동 폭
$650.01
$1,002.16
알제넥스 NV ADR Stock (ARGX) Company Profile
Compare ARGX vs VRTX, REGN, RVMD, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ARGX
Argen X Se Adr
|
990.58 | 53.26B | 4.16B | 1.29B | 734.26M | 19.58 |
VRTX
Vertex Pharmaceuticals Inc
|
520.66 | 128.19B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
811.46 | 82.72B | 14.92B | 4.42B | 3.79B | 41.04 |
RVMD
Revolution Medicines Inc
|
213.46 | 43.66B | 742.00K | -1.37B | -1.07B | -7.0731 |
ONC
Beone Medicines Ltd Adr
|
367.13 | 39.31B | 5.76B | 514.49M | 1.10B | 4.4813 |
알제넥스 NV ADR Stock (ARGX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-03-10 | 업그레이드 | Deutsche Bank | Hold → Buy |
| 2025-12-18 | 다운그레이드 | Robert W. Baird | Outperform → Neutral |
| 2025-11-24 | 다운그레이드 | Wolfe Research | Outperform → Peer Perform |
| 2025-09-15 | 재개 | Truist | Buy |
| 2025-09-11 | 다운그레이드 | Deutsche Bank | Buy → Hold |
| 2025-08-25 | 개시 | RBC Capital Mkts | Outperform |
| 2025-07-08 | 업그레이드 | Deutsche Bank | Hold → Buy |
| 2025-07-03 | 재개 | Morgan Stanley | Overweight |
| 2025-05-13 | 업그레이드 | Robert W. Baird | Neutral → Outperform |
| 2025-03-17 | 업그레이드 | Bernstein | Mkt Perform → Outperform |
| 2025-03-12 | 업그레이드 | Deutsche Bank | Sell → Hold |
| 2025-01-17 | 다운그레이드 | Deutsche Bank | Hold → Sell |
| 2024-11-12 | 업그레이드 | Wolfe Research | Peer Perform → Outperform |
| 2024-11-05 | 업그레이드 | Scotiabank | Sector Perform → Sector Outperform |
| 2024-11-01 | 다운그레이드 | Robert W. Baird | Outperform → Neutral |
| 2024-11-01 | 업그레이드 | William Blair | Mkt Perform → Outperform |
| 2024-10-10 | 재개 | Raymond James | Strong Buy |
| 2024-10-04 | 다운그레이드 | Deutsche Bank | Buy → Hold |
| 2024-08-06 | 업그레이드 | Barclays | Equal Weight → Overweight |
| 2024-07-25 | 업그레이드 | Deutsche Bank | Hold → Buy |
| 2024-07-23 | 업그레이드 | Oppenheimer | Perform → Outperform |
| 2024-02-15 | 개시 | Wolfe Research | Peer Perform |
| 2023-12-20 | 다운그레이드 | Deutsche Bank | Buy → Hold |
| 2023-12-20 | 다운그레이드 | William Blair | Outperform → Mkt Perform |
| 2023-07-31 | 개시 | Scotiabank | Sector Perform |
| 2023-07-24 | 다운그레이드 | UBS | Buy → Neutral |
| 2023-07-17 | 재개 | Evercore ISI | Outperform |
| 2023-06-15 | 개시 | Societe Generale | Sell |
| 2023-05-31 | 개시 | UBS | Buy |
| 2023-04-25 | 개시 | Citigroup | Buy |
| 2023-03-14 | 업그레이드 | Robert W. Baird | Neutral → Outperform |
| 2022-12-07 | 개시 | William Blair | Outperform |
| 2022-10-12 | 개시 | Oppenheimer | Perform |
| 2022-07-29 | 다운그레이드 | Robert W. Baird | Outperform → Neutral |
| 2022-06-28 | 재개 | Stifel | Buy |
| 2022-05-03 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2021-12-08 | 개시 | Wells Fargo | Overweight |
| 2021-11-29 | 업그레이드 | Piper Sandler | Neutral → Overweight |
| 2021-10-29 | 업그레이드 | Guggenheim | Neutral → Buy |
| 2021-10-28 | 업그레이드 | Raymond James | Outperform → Strong Buy |
| 2021-10-07 | 개시 | Jefferies | Buy |
| 2021-09-23 | 업그레이드 | Redburn | Neutral → Buy |
| 2021-09-07 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2021-07-23 | 개시 | Deutsche Bank | Hold |
| 2021-07-19 | 재개 | Wolfe Research | Outperform |
| 2021-06-18 | 개시 | UBS | Buy |
| 2021-06-04 | 재개 | Robert W. Baird | Outperform |
| 2021-05-10 | 업그레이드 | H.C. Wainwright | Neutral → Buy |
| 2021-04-23 | 개시 | Redburn | Neutral |
| 2021-03-05 | 재확인 | H.C. Wainwright | Neutral |
| 2021-02-02 | 다운그레이드 | Piper Sandler | Overweight → Neutral |
| 2021-01-04 | 다운그레이드 | Guggenheim | Buy → Neutral |
| 2020-08-25 | 개시 | Raymond James | Outperform |
| 2020-08-19 | 다운그레이드 | Evercore ISI | Outperform → In-line |
| 2020-07-29 | 개시 | H.C. Wainwright | Neutral |
| 2020-02-10 | 개시 | BofA/Merrill | Buy |
| 2019-11-05 | 개시 | Credit Suisse | Neutral |
| 2019-10-31 | 업그레이드 | William Blair | Mkt Perform → Outperform |
| 2019-10-22 | 개시 | JP Morgan | Overweight |
| 2019-09-27 | 개시 | Wells Fargo | Market Perform |
| 2019-09-16 | 재개 | Cowen | Outperform |
| 2019-06-28 | 개시 | Robert W. Baird | Outperform |
| 2019-01-18 | 재개 | SunTrust | Buy |
| 2019-01-04 | 개시 | Morgan Stanley | Overweight |
| 2018-12-17 | 개시 | Goldman | Buy |
| 2018-12-14 | 개시 | Wolfe Research | Outperform |
| 2018-06-29 | 개시 | Nomura | Buy |
| 2018-04-09 | 개시 | SunTrust | Buy |
| 2018-01-29 | 재확인 | JMP Securities | Mkt Outperform |
모두보기
알제넥스 NV ADR 주식(ARGX)의 최신 뉴스
Strong Argenx stock extends rally after Vyvgart trial win and analyst target hikes. - AD HOC NEWS
Citizens raises argenx stock price target to $1,200 on trial results - Investing.com
Argenx's Positive Vyvgart Data in Autoimmune Indication Supports Growth and FB102 Broadens Portfolio - Morningstar
Resilient Argenx stock jumps after positive Vyvgart Phase 3 data - AD HOC NEWS
TD Cowen raises argenx stock price target to $1,353 on myositis outlook - Investing.com
Gold Gains 1%; NY Empire State Manufacturing Index Rises In August - Benzinga
European ADRs Started The Week Slightly Higher In US Trading - finimize.com
There are notable gap-ups and gap-downs in today's session. - ChartMill
H World Group Posts Upbeat Q2 Results, Joins Almonty Industries, Diana Shipping And Other Big Stocks Movi - Benzinga
Argx stock hits all-time high at 954.5 USD By Investing.com - Investing.com Canada
argenx SE (ARGX) Stock Price, News, Quote & History - Yahoo Finance
argenx reports positive Phase 3 ALKIVIA results - grafa.com
Zai Lab, argenx report positive phase 3 data for myositis drug - Investing.com India
Why is Argen-X stock surging today? - Investing.com
Why is Argen-X stock surging today? By Investing.com - Investing.com India
Argenx shares jump after positive Phase 3 results in autoimmune myositis trial - Investing.com South Africa
T. Rowe Price (ARGX) discloses 2.68M argenx SE ADRs with 4.3% ownership - Stock Titan
Forte Biosciences earnings on deck as $2.2 billion argenx deal nears - Investing.com
Argenx stock holds near recent highs as half year 2026 update and Forte deal shape outlook - AD HOC NEWS
Weekly Recap: Cash tender offer for Forte and EGM on director appointments - TradingView
Galapagos ADR Representing Ord Shs (LKFT) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
argenx launches tender offer for Forte Biosciences at $77 per share - Investing.com
The Charts Reveal Significant Price Movement in Forte Biosciences Stock Ahead of Argenx’s Acquisition Announcement - Barchart.com
Argenx stock price target held at $940 by H.C. Wainwright on acquisition - Investing.com South Africa
Crude Oil Falls Sharply; US Durable Goods Orders Increase 0.3% In June - Benzinga
Baker Hughes Posts Upbeat Q2 Earnings, Joins Forte Biosciences, Eikon Therapeutics And Other Big Stocks M - Benzinga
argenx SE (ARGX) stock price, news, quote and history - Yahoo Finance UK
argenx to buy Forte Biosciences in a deal worth $2.2 billion - grafa.com
Why Forte Biosciences Shares Are Trading Higher By 39%; Here Are 20 Stocks Moving Premarket - Benzinga
Argenx to buy Forte Biosciences for $2.2 billion to expand immunology pipeline - Investing.com UK
Baker Hughes Posts Upbeat Q2 Earnings, Joins Forte Biosciences, Eikon Therapeutics And Other Big Stocks Moving Higher On Monday - Sahm
Weekly Recap: Q2 sales and profit surge and Empasiprubart readout schedule - TradingView
argenx SE Sponsored ADR Revenue Breakdown – DUS:1AEA - TradingView
Analysts Offer Insights on Healthcare Companies: Tempus AI, Inc. Class A (TEM), Brainsway (BWAY) and Argenx Se (ARGX) - The Globe and Mail
argenx SE ADR Unsponsored Brazilian Depositary Receipt Repr 0.04 ADR - TradingView
RBC Capital raises argenx stock price target to $1,025 on strong Vyvgart sales - Investing.com
H.C. Wainwright reiterates argenx stock rating on strong sales - Investing.com
Guggenheim raises argenx stock price target to $1,185 on strong sales - Investing.com
Citizens cuts argenx stock price target to $932 on valuation - Investing.com
Citizens cuts argenx stock price target to $932 on valuation By Investing.com - Investing.com Canada
Argenx's Robust Vyvgart Growth Drives Margin Expansion as Pipeline Advances - Morningstar
European ADRs Slipped In US Trading Late Thursday - finimize.com
argenx Q2 2026 slides: 60% sales growth, seronegative gMG expansion - Investing.com
argenx ADR earnings beat by $0.97, revenue topped estimates - Investing.com
Argenx soars on strong Vyvgart sales, beating estimates By Investing.com - Investing.com Canada
Argenx shares jump on Vyvgart sales beat, pipeline readouts ahead By Investing.com - Investing.com Nigeria
Argenx soars on strong Vyvgart sales, beating estimates - Investing.com
argenx SE (ARGNF) Q2 2026 Earnings Call Highlights: Robust Growth and Strategic Advances By GuruFocus - Investing.com Canada
BR:A1RG34 Stock Latest News - TipRanks
Argenx Reports Half Year 2026 Financial Results and Provides Second Quarter Business Update - marketscreener.com
Argenx Se (ARGX) Receives a Buy from Guggenheim - The Globe and Mail
알제넥스 NV ADR (ARGX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.67%
0.89%
자본화:
|
볼륨(24시간):